JW Shinyak Corp
KOSDAQ:067290
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 256.1906
2 210
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
J
|
JW Shinyak Corp
KOSDAQ:067290
|
112.9B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
528.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
220.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
271.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
148.1B USD |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
JW Shinyak Corp
Glance View
JW SHINYAK Corp. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2003-02-11. The Company’s main products portfolio consists of antibiotics, anesthetics, respiratory remedies, urology remedies, cardiovascular remedies, allergy remedies, digestive remedies, anti-inflammatory drugs, antivirals as well as acne remedies, among others. In addition, it also involves in the provision of cosmetics, such as creams, cleansers, toners, essences, lotions and others.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for JW Shinyak Corp is 4.1%, which is above its 3-year median of 3.7%.
Over the last 3 years, JW Shinyak Corp’s Operating Margin has decreased from 4.9% to 4.1%. During this period, it reached a low of -32.4% on Mar 31, 2024 and a high of 13.9% on Sep 30, 2024.